Change in dilation effect of prednisone at the different stages of COPD

N. Kuzubova, E. Lebedeva, A. Fedin (Saint-Petersburg, Russian Federation)

Source: Annual Congress 2011 - Models of disease and drug actions
Session: Models of disease and drug actions
Session type: Poster Discussion
Number: 1774
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Kuzubova, E. Lebedeva, A. Fedin (Saint-Petersburg, Russian Federation). Change in dilation effect of prednisone at the different stages of COPD. Eur Respir J 2011; 38: Suppl. 55, 1774

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Effect of ICS withdrawal on COPD exacerbations in patients on triple therapy at baseline
Source: International Congress 2018 – COPD management
Year: 2018


Comparison of the effect of short course of oral prednisone in patients with moderate and severe persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 281s
Year: 2003

Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use
Source: Eur Respir J 2001; 18: Suppl. 33, 514s
Year: 2001

Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanib
Source: International Congress 2015 – Treatment of IPF
Year: 2015


Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021


Effect of low dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real life study
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021


The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use
Source: Eur Respir J 2001; 18: Suppl. 33, 515s
Year: 2001

Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility
Source: Eur Respir J 2002; 20: Suppl. 38, 243s
Year: 2002

Treatment efficacy of idiopathic pulmonary fibrosis depending on the dose difference of pirfenidone
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Year: 2020

Effect of high or low-medium accumulated dose regimes of systemic corticosteroids for hospitalised patients with exacerbated chronic obstructive pulmonary disease: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials
Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data
Year: 2021



Effects of respiratory rehabilitation in patients with different stages of COPD severity
Source: Annual Congress 2009 - Pulmonary rehabilitation: extending the scope and benefit of rehabilitation for patients with chronic respiratory disease
Year: 2009

Effect of treatment on conditioning function indices in COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 296s
Year: 2005

Evaluating the effects of pulmonary rehabilitation in patients with COPD in early and late disease stages.
Source: Annual Congress 2008 - Impact of rehabilitation programmes in COPD and non-COPD patients
Year: 2008

The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


The effect of prednisone treatment on lung function test parameters in patients with chronic sarcoidosis
Source: Eur Respir J 2002; 20: Suppl. 38, 433s
Year: 2002

Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2007; 30: Suppl. 51, 357s
Year: 2007

Effect of theophylline in low and average doses on lung function and quality of life in patients with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 212s
Year: 2006

Predictors of the level of daily activities for different GOLD COPD stages
Source: Eur Respir J 2007; 30: Suppl. 51, 127s
Year: 2007

Evaluation of the individual bronchodilator response in patients with severe COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 246s
Year: 2002

Acute effects of higher than customary doses of salmeterol (SM) and salbutamol (SB) in patients with acute exacerbation of COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 514s
Year: 2001